Breaking New Ground: Our Research Site Enrolls First Patient in the US!
Premier Pain Treatment Institute (PPTI) is proud to announce a groundbreaking achievement in medical research: the enrollment of the first patient in the United States for the Neural Panel Study sponsored by Saluda. This significant milestone not only marks a pivotal moment for PPTI but also signals a leap forward in advancing patient care and treatment methodologies for chronic pain. With this enrollment, PPTI reaffirms its commitment to pioneering cutting-edge solutions and setting the standard for excellence in medical research.
The Neural Panel Study, sponsored by Saluda, focuses on evaluating the clinical utility of neurophysiological measurements of ECAP-controlled closed-loop Spinal Cord Stimulation (SCS) to guide treatment for patients suffering from chronic pain of the trunk and/or limbs. This innovative approach represents a paradigm shift in pain management, utilizing advanced technology to tailor therapies to individual patient needs. Unlike traditional SCS systems with fixed settings, the Evoke System adapts dynamically, offering personalized treatment based on real-time feedback.
The study, which will span six months for each patient, aims to enroll 250 participants across 25 sites in the United States, with PPTI contributing at least ten patients. The primary objective of the study is to assess the efficacy of the neural panel metrics in guiding patient therapy and characterizing clinical outcomes. By leveraging ECAP-controlled closed-loop SCS, researchers seek to optimize pain relief while minimizing adverse effects, thereby enhancing the quality of life for patients dealing with chronic pain.
The Evoke Spinal Cord Stimulation (SCS) System, the focal point of the study, measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude. This closed-loop system represents a significant advancement in pain management technology, offering patients a more precise and adaptive treatment approach. Through the Neural Panel Study, researchers aim to validate the clinical utility of this innovative system and pave the way for its widespread adoption in pain management practices.
As PPTI celebrates this milestone achievement, it remains dedicated to driving innovation in pain management and improving patient outcomes. The enrollment of the first patient in the US for the Neural Panel Study underscores PPTI’s leadership in medical research and its unwavering commitment to enhancing the lives of individuals living with chronic pain. With this groundbreaking study, PPTI and its partners are poised to revolutionize the field of pain management, offering hope and relief to countless patients across the nation.
More information about our current and previous clinical research studies can be found on our Clinical Research page.
The team from Saluda with Premier Pain Treatment Institute’s Dr. Michael Danko and Research Coordinator Dr. Emily Bell.
